Performance of noninvasive fibrosis indices in chronic hepatitis B during pretreatment and post-treatment periods

Biomark Med. 2023 Oct;17(19):799-809. doi: 10.2217/bmm-2023-0405. Epub 2024 Jan 5.

Abstract

Background: Pretreatment and post-treatment performances of noninvasive fibrosis indices were determined in patients with chronic hepatitis B. Method: This was a retrospective, single-center study. Results: The best area under the receiver operating characteristic curve values were detected for aspartate aminotransferase-to-alanine aminotransferase ratio (0.685) for ≥F2, Fibrosis Index (FI; 0.703) for ≥F3; FI (0.872) for ≥F4 and FI (0.864) for cirrhosis. After antiviral treatment, the best area under the receiver operating characteristic curve values were detected in aspartate aminotransferase-to-alanine aminotransferase ratio (0.615) for ≥F2; in FI based on four factors (FIB-4; 0.634) for ≥F3; in FIB-4 (0.678) for ≥F4 and in FIB-4 (0.814) for cirrhosis. Conclusion: FIB-4 and FI showed better performance in defining advanced fibrosis (≥F4) and cirrhosis.

Keywords: AAR; APRI; FI; FIB-4; chronic hepatitis B.

MeSH terms

  • Alanine Transaminase
  • Aspartate Aminotransferases
  • Biomarkers
  • Biopsy
  • Fibrosis
  • Hepatitis B, Chronic* / complications
  • Hepatitis B, Chronic* / drug therapy
  • Humans
  • Liver Cirrhosis / diagnosis
  • Platelet Count
  • ROC Curve
  • Retrospective Studies

Substances

  • Alanine Transaminase
  • Aspartate Aminotransferases
  • Biomarkers